← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,206	+11	+0.5%	$197B
2	2 Pfizer PFE $166B	1,969	-1	-0.1%	$136B
3	3 Merck MRK $364B	1,745	-10	-0.6%	$108B
4	4 AbbVie ABBV $501B	1,640	+3	+0.2%	$63.4B
5	5 Gilead Sciences GILD $190B	1,632	+2	+0.1%	$98.3B
6	6 Bristol-Myers Squibb BMY $121B	1,524	-11	-0.7%	$78.8B
7	7 Amgen AMGN $230B	1,436	-19	-1%	$90.4B
8	8 Novartis NVS $279B	876	-51	-6%	$17.3B
9	9 GSK GSK $95.9B	727	+8	+1%	$8.39B
10	10 Regeneron Pharmaceuticals REGN $80.1B	550	-27	-5%	$26.2B
11	11 AstraZeneca AZN $251B	390	0	0%	$7.26B
12	12 Incyte INCY $22.6B	359	-22	-6%	$13B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	340	-6	-2%	$7.13B
14	14 Opko Health OPK $1.02B	259	-14	-5%	$1.19B
15	15 Myriad Genetics MYGN $397M	234	+1	+0.4%	$3.07B
16	16 DELISTED Assertio ASRT	196	-10	-5%	$901M
17	SGEN 17 DELISTED Seagen Inc. Common Stock SGEN	194	-37	-16%	$4.96B
18	18 Precigen PGEN $2.64B	191	+11	+6%	$3.42B
19	19 DELISTED Exact Sciences EXAS	167	-16	-9%	$546M
20	20 Halozyme HALO $13.3B	161	-5	-3%	$974M
21	21 Exelixis EXEL $15.1B	144	-2	-1%	$710M
22	22 DELISTED Radius Health, Inc. RDUS	144	-4	-3%	$1.29B
23	23 DELISTED Immunogen Inc IMGN	143	-9	-6%	$656M
24	24 DELISTED Lumos Pharma, Inc. Common Stock LUMO	139	-13	-9%	$309M
25	25 DELISTED Merrimack Pharmaceuticals, Inc. MACK	139	0	0%	$709M